Abstract. The past two decades have seen a drastic increase in obesity rates in Western societies and emerging countries. As such, it has become increasingly important to understand the molecular mechanisms by which obesity affects the risk of developing associated co-morbidities. The present study aimed at identifying the effect of insulin on breast cancer and breast epithelial cells, reflective of obesity-associated hyperinsulinaemia, as a molecular explanation for the increased risk of oestrogen receptor-negative postmenopausal breast cancer in obese women. Both of the examined breast cancer cell lines (MDA-MB-231 and SK-BR-3) showed intact insulin signalling (insulin receptor phosphorylation and activation of phosphoinositol-3 kinase and mitogen-activated protein kinase cell signalling pathways), with MDA-MB-231 cells showing aberrantly amplified insulin signalling. Insulin did not induce a physiologically significant change in proliferation or apoptosis in either cell line. MDA-MB-231 cells showed decreased cell proliferation and increased S-phase population, while SK-BR-3 cells showed increased cyclin D and cyclin E gene expression and increased necrosis after insulin treatment. Hyperinsulinaemia may not be a universal mechanism by which obesity affects breast cancer progression. Normal breast epithelial cells (MCF-10A) showed intact insulin signalling, increased cell proliferation and reduced apoptosis after insulin treatment, suggesting cell growth and survival-promoting effects of insulin on these cells. Thus, hyperinsulinaemia may affect breast cancer aetiology rather than progression and this finding may provide a novel molecular mechanism for the role of insulin in the promotion of increased postmenopausal breast cancer risk in obese women.
Introduction
Latest statistics show that obesity affects more than 1/3 of the adult population in the United States, with higher incidences in women (1, 2) . With postmenopausal breast cancer incidence and mortality rates closely correlated with obesity (3), it is imperative to explore the underlying molecular mechanisms of this connection, as an increasing number of female patients will be in the obese postmenopausal group in the near future. Obesity is associated with concentration changes in the endocrine secretion profile of white adipose tissue. These changes, amongst others, contribute to the link between obesity and hyperinsulinaemia (4) . Hyperinsulinaemia is consistently linked with increased breast cancer risk and mortality. An epidemiological study demonstrated a positive correlation between increased insulin resistance and increased risk of all cancers, even in nonobese individuals (5) . A meta-analysis indicated an increased risk of development of and mortality from breast cancer in diabetic women (6) . Another meta-analysis, examining C-peptide concentrations and breast cancer risk, showed a positive correlation in case/control studies (7) . A large cohort study additionally observed a positive correlation between hyperinsulinaemia and breast cancer in their non-fasting postmenopausal sub-group (8) . Additionally, fasting insulin concentrations at a young age were directly related to increased breast cancer incidences in later life (9) . Similarly, in a case control study of Chilean women, insulin resistance was identified as a risk factor for developing breast cancer in postmenopausal women (10) . Interestingly, in contrast to overall obesity, assessed by BMI, hyperinsulinaemia has also been linked to premenopausal breast cancer (11, 12) , although this association was not consistently observed (13) . Additionally, recent findings suggest that the combined effects of obesity and insulin resistance elevate certain biochemical markers generally associated with an increased risk of developing premenopausal breast cancer (14) .
Previous studies have indicated that the main effect of obesity on breast cancer incidence rates is mediated by increasing oestrogen levels in obese postmenopausal women (15, 16) . While the connection between obesity and oestrogen receptor (ER)-negative breast cancer incidence rates is lower than between obesity and ER-positive breast cancer, this association still indicates a connection between obesity and breast cancer, independent of oestrogen. Given the known interaction between the insulin receptor (IR) and oestrogen (17) , this study used ER-negative cell lines.
In in vitro studies, high insulin concentrations increased cell growth in a number of cell lines (18, 19) , including breast cancer cell lines (20, 21) . The breast cancer cell line, MCF-7, is a wellestablished model of an ER-positive breast cancer. Stimulation with up to 100 nM insulin has been shown to increase the ability of these cells to incorporate leucine and thymidine (20) , increase fatty acid synthesis (22) , increase cell cycle progression (23), protect against apoptosis (24) , downregulate protein degradation and promote an increase in cell size (25) . Treatment of MDA-MB-231 cells and other ER-negative breast cancer cell lines with up to 1 µM insulin did not increase cell proliferation or affect apoptosis (21, 26) . Conversely, MDA-MB-231 breast cancer cells have an elevated IR content as they carry an uncommon IR gene amplification (27) , indicating that insulin may play a role in the metabolism of this cell line.
In this study, the influence of high insulin concentrations (100 nM) on several molecular aspects in breast cancer cells and breast epithelial cells was assessed. MDA-MB-231 and SK-BR-3 breast cancer cells were used to identify the impact of hyperinsulinaemia on oestrogen-independent breast cancer progression. MCF-10A cells were used representatively of normal breast epithelial cells to examine the impact of hyperinsulinaemia on breast cancer aetiology. Changes in insulin receptor phosphorylation, cell proliferation, activation of cell signalling pathways, changes in cell cycle and early apoptosis were determined. (28) . The serum-free medium used was RPMI-1640 (25 mM HEPES, 1X glutamax) (Gibco) supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco) for MDA-MB 231 and SK-BR-3 cells and DMEM/F12 (Bio-Whittaker) supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin for MCF-10A cells. Cell culture conditions were 37˚C in humidified air containing 5% CO 2 .
Materials and methods

Materials
Cell proliferation assay. Cell proliferation was detected using a colorimetric Cell Proliferation ELISA kit (Roche Diagnostics, Penzberg, Germany; Cat no. 11 647 229 001), which assesses DNA replication by measuring bromodeoxyuridine (BrdU) incorporation. Cells (5x10 3 /well of each cell line) were plated in 96-well plates (Fisher Scientific; Cat no. 167008) with 100 µl/ well growth medium and incubated for 24 h at 37˚C. Cells were washed once in 100 µl/well sterile PBS and incubated in serumfree medium for 24 h. Cells were then washed as described above and treated for 24 or 48 h with 100 nM insulin in 100 µl/ well serum-free medium. During treatment, the medium was supplemented with 10 µM BrdU for the final 24 h of treatment. Incorporated BrdU was detected according to the manufacturer's instructions and colour development was quantified on a µQuant Microplate Spectrophotometer (BioTek, Potton, UK) by measuring absorption at 450 nm with a reference wavelength of 690 nm. Three experiments were performed for each cell line and each time-point. Each experiment consisted of six replicates for each treatment, i.e. six wells for the control and six wells for the treatment groups.
Insulin receptor phosphorylation assay. In 60-mm 2 tissue culture dishes (Fisher Scientific; Cat no. 150288), 1x10 6 cells of each of the three cell lines were plated and incubated in 3 ml growth medium for 24 h at 37˚C. Cells were starved as described above and treated with 100 nM insulin for 2 min at 37˚C. IR phosphorylation was determined using the DuoSet IC human phospho insulin receptor kit (R&D Systems, Abingdon, UK; Cat no. DYC2718) following the manufacturer's instructions. In brief, cell lysate was prepared after treatment and added to a 96-well ELISA plate coated with 100 µl/well of supplied capture antibody, targeting the IR β-subunit, at 8 µg/ml. Detection was achieved by adding the supplied secondary antibody (100 µl/ well), tagged with horseradish-peroxidase (HRP) and diluted 1:1,000, and by adding 100 µl of a stable peroxide solution and tetramethylbenzidine solutions (R&D Systems; Cat no. DY999), mixed 1:1, to each well. Absorption was quantified at 450 nm with a correction wavelength of 540 nm on a µQuant microplate spectrophotometer (BioTek). Three experiments were performed for each cell line.
Phospho-kinase ELISA. Cell-based ELISA Phospho-AKT (S473) Immunoassay (Cat no. KCB887) and Phospho-ERK1/ ERK2 (T202/Y204) Immunoassay (Cat no. KCB1018) were purchased from R&D Systems. Cells were grown and starved as before and treated as indicated in Fig. 3 . The phosphorylation of protein kinase B (PKB/AKT) and extracellular-regulated kinase (ERK)1/2 was then assessed following the manufacturer's instructions. In brief, after fixing, the cells were incubated with phospho-AKT-or phospho-ERK1/2-specific mouse antibodies in conjunction with anti-total AKT-or anti-total ERK1/2-specific rabbit antibodies, respectively. Phosphorylated and total protein was detected with species-specific secondary antibodies tagged with HRP and alkaline phosphatase (AP), respectively. Two different fluorescent substrates were used for quantification. Fluorescence was measured on a Fluoroskan Ascent microplate reader (Lab Systems, Hull, UK) with excitation at 544 nm and emission at 590 nm (phosphorylated protein) and excitation at 355 nm and emission at 460 nm (total protein). For each cell line three experiments were performed to assess AKT phosphorylation and three to assess ERK1/2 phosphorylation after insulin treatment. Each experiment included two replicates for each treatment time and the control.
Flow cytometry
Cell cycle. Changes in the cell distribution across cell cycle stages were assessed by measurement of DNA content in the cells. The DNA specific dye used was propidium iodide (PI) (Sigma, Cat no. P4170). Cells were plated at 5x10 5 cells/well in six-well plates with 3 ml growth medium and incubated for 24 h at 37˚C. Cells were starved for 24 h and then treated with 100 nM insulin for 24 h. Cells were harvested, stained and analysed as previously described (28) . Three experiments were performed for each cell line, containing two replicates for the control and treatment groups.
Apoptosis. The Annexin V-FITC/7-AAD apoptosis kit (Beckman Coulter; Cat no. IM3614) was used to examine apoptosis following insulin treatment. The cells were grown (1x10 6 /dish) and treated with 100 nM insulin in 60-mm 2 dishes as described above. After the cells had been treated and collected, 100 µl of 1X binding buffer (supplied), 10 µl Annexin V-FITC (supplied) and 20 µl 7-AAD dye (supplied) were added to each tube. The samples were incubated on ice in the dark for 15 min. The samples were then diluted 1:5 prior to analysis. Flow cytometry of the Annexin V-and 7-AAD-stained cells was performed using a Coulter Epics XLMCL flow cytometer (Beckman Coulter). Data were analysed using EXPO-32 Software (Applied Cytometry Systems, Sheffield, UK). Apoptotic cells were captured by linear FL-2 vs. area plots, with a cell line-specific upper cut-off point. Necrotic cells were similarly captured by linear FL-4 vs. area plots. Numbers were assessed after 10,000 events. Three experiments were performed for each cell lines with two replicates for the control and treatment groups.
RT-PCR. Cells were grown (1x10 6 /dish) and treated with 100 nM insulin in 60-mm 2 dishes as described above. After the cells were treated, total-RNA was extracted using TRIzol (Invitrogen; Cat no. 15596). The extracted RNA (1 ng for cyclin E and 68˚C for β-actin) and 2 min at 72˚C were performed. This was followed by a 10-min final extension step at 72˚C. PCR-products were separated on 1% agarose gels, images captured by GelDoc CCD imaging (Bio-Rad) and quantified by Quantity-One software (Bio-Rad).
Results
Effect of insulin on cell proliferation. In MDA-MB-231 cells, 100 nM insulin treatment for 24 h did not increase cell proliferation; after 48 h of insulin treatment cell proliferation decreased by 18% (p<0.001) compared to the untreated control. Cell proliferation did not change in SK-BR-3 cells after 24 or 48 h of treatment with 100 nM insulin. In MCF-10A cells, proliferation increased by 184% (p<0.001) after 24 h of insulin treatment and by 34% (p<0.001) after 48 h of treatment compared to the untreated control (Fig. 1) .
Effect of insulin treatment on IR phosphorylation.
In MDA-MB-231 cells, IR phosphorylation increased by 380% (p<0.001) following 2 min of treatment with 100 nM insulin compared to the untreated control. In SK-BR-3 cells, the increase in IR phosphorylation was 35% (p<0.001) and 38% (p<0.001) in MCF-10A cells after 2 min of treatment compared to the untreated control (Fig. 2) . Effect of insulin on cell signalling pathways. In MDA-MB-231 cells, AKT phosphorylation increased by 294% after 5 min (p<0.001) and by 141% after 10 min (p<0.001) of treatment with 100 nM insulin compared to the untreated control. ERK1/2 phosphorylation did not change significantly after 5 or 10 min of insulin treatment. The phosphorylation of ERK1/2 increased by 95% after 15 min (p<0.001) and by 148% after 20 min (p<0.001) of treatment with 100 nM insulin (Fig. 3A) compared to the untreated control. In SK-BR-3 cells, AKT phosphorylation increased by 67% after 5 min (p<0.001) of treatment with 100 nM insulin and no significant change in AKT-phosphorylation was observed after 10 min of treatment. The phosphorylation of ERK1/2 decreased by 15, 20 and 23% after treatment with 100 nM insulin for 5 (p=0.016), 10 (p=0.002) and 15 min (p<0.001), respectively, but did not significantly change after 20 min of insulin treatment compared to the untreated control (Fig. 3B) . In MCF-10A cells, AKT phosphorylation increased by 75% after 5 min (p= 0.022) of treatment with 100 nM insulin and no statistically significant change was observed after 10 min of insulin treatment. The phosphorylation of ERK1/2 increased by 29% after 10 min (p=0.002) of treatment with 100 nM insulin compared to the untreated control. No statistically significant change was observed at any other time-point (Fig. 3C) .
Effect of insulin on cell cycle. In MDA-MB-231 cells, the S-phase population increased by 1.7 percentage points after 24 h (p=0.002) of treatment with 100 nM insulin compared to the S-phase population of the control cells (Fig. 4A) . In SK-BR-3 and MCF-10A cells, treatment with 100 nM insulin did not significantly change the distribution of the cell population across the cell cycle phase (Fig. 4B and C) . In MDA-MB-231 and MCF-10A cells, cyclin D and cyclin E gene expression did not significantly change after up to 120 min of treatment with 100 nM insulin compared to the untreated control ( Fig. 5A and C) . In SK-BR-3 breast cancer cells, cyclin D gene expression increased by 18% after 15 min (p=0.005) of treatment with 100 nM insulin compared to the untreated control. Cyclin E gene expression increased by 22% after 15 min (p<0.001), by 19% after 30 min (p=0.002), by 17% after 60 min (p=0.003) and by 15% after 120 min (p=0.012) of treatment with 100 nM insulin compared with the untreated control (Fig. 5B) .
Effect of insulin on apoptosis.
In MDA-MB-231 breast cancer cells, treatment with 100 nM insulin did not significantly change Annexin V detection or 7-AAD staining after 24 h of treatment (Fig. 6A) . In SK-BR-3 breast cancer cells, Annexin V detection did not change significantly after 24 h of treatment with 100 nM insulin. The percentage of cells with high levels of 7-AAD staining increased significantly by 9% after 24 h (p=0.024) of 100 nM insulin treatment (Fig. 6B) . In MCF-10A breast epithelial cells, Annexin V detection decreased significantly by 13% after 24 h (p=0.037) of treatment with 100 nM insulin compared to the untreated control. The amount of cells with high levels of 7-AAD staining did not change significantly after 24 h of treatment with 100 nM insulin (Fig. 6C) .
Discussion
The epidemiological link between obesity and breast cancer lacks a fundamental molecular mechanism explaining this connection. Insulin may be a molecular mediator of the obesity-breast cancer connection (29) . Previous in vitro studies have indicated that insulin increases cell proliferation in ER-positive, but not in ER-negative breast cancer cells (20, 21, 26, 30) . On the other hand, epidemiologically insulin and C-peptide levels have been linked to an increased risk of ER-negative breast cancer (31) . This suggests an additional mode of action of insulin to increase breast cancer risk. Thus, in the present study, we investigated the effect of insulin on ER-negative cell lines to elucidate the impact of insulin independently of ER. Previously, when MDA-MB-231 breast cancer cells were treated with 100 nM insulin, no increase in cell proliferation after 24 h was observed (21) . Similarly, in the present study, we observed no increase in cell proliferation in this cell line after 24 h of treatment and a statistically significant decrease after 48 h of treatment, which may not be of physiological importance. In a previous study, it was concluded that the overexpression of glycoprotein PC-1 led to an inhibition of IR-autophosphorylation and consequently to a complete inhibition of insulin signalling in MDA-MB-231 breast cancer cells (32) . Conversely, in the present study, we observed an increase in IR, AKT and ERK1/2 phosphorylation after insulin treatment, suggesting that insulin signalling in these cells is intact. Additionally a slight but statistically significant increase in the S-phase population was observed after insulin treatment, suggesting a potential effect of insulin on cell cycle progression. This observation however, was not supported by changes in cyclin D or cyclin E gene expression, indicating that the precise impact of insulin on the cell cycle in MDA-MB-231 breast cancer cells remains unclear. There was also no indication that insulin reduced apoptosis in these cells. A comparison to SK-BR-3 breast cancer cells and MCF-10A breast epithelial cells indicated that insulin signalling was amplified in these cells. However, this signal did not translate into significantly altered physiological changes. Thus, insulin may play a role in MDA-MB-231 cell metabolism, but not in increasing cell proliferation and in enhancing cell cycle progression or in decreasing apoptosis.
A second ER-negative breast cancer cell line, SK-BR-3, also showed no indications of increased cell proliferation after treatment with 100 nM insulin for up to 48 h. Further similarities to the MDA-MB-231 breast cancer cell line were the increase in IR and AKT phosphorylation. This increase, while statistically significant, did not reach the same level as in the MDA-MB-231 breast cancer cell line. This may be explained by the previously observed IR gene amplification in MDA-MB-231 breast cancer cells, which translated into the increased phosphorylation of * p<0.05, ** p<0.01, *** p<0.001, denotes a significant difference compared to the control, obtained using Dunnett's post hoc t-test following univariate analysis of variance.
IR and IR targets, such as AKT and ERK1/2, when compared to the other cell lines (33) . Additionally, MDA-MB-231 breast cancer cells have mutated Raf and Ras genes [members of the mitogen-activated protein kinase (MAPK) pathway], which may explain the difference in phosphorylation levels between the two breast cancer cell lines (34) . Interestingly, ERK1/2 phosphorylation decreased with the insulin treatment of SK-BR-3 cells. This is in contrast to both MDA-MB-231 and MCF-10A cells, which showed increased ERK1/2 phosphorylation after insulin treatment, suggesting that this decrease is unique to the SK-BR-3 cells. An explanation may be that insulin interferes with an underlying autocrine stimulus in these cells, which utilizes the MAP-kinase pathway but becomes inhibited as insulin signalling initiates changes in the same pathway. There was a significant increase in cyclin D and cyclin E gene expression after insulin treatment in SK-BR-3 breast cancer cells, indicating that insulin may increase cell cycle progression. As in MDA-MB-231 breast cancer cells, however, this observation was not supported by changes in cell population distribution across the cell cycle stages, which remained unaffected by insulin treatment of these cells. From these results, increased cell cycle progression cannot be predicted with a high degree of confidence in these cells. Furthermore, there was a small yet significant increase in necrosis with insulin treatment, which on its own would suggest cytotoxicity of insulin in these cells. Physiologically, these changes of increased cyclin expression and increased necrosis may be negligible, especially as they are seemingly contradictory and not supported by the additional analyses. Thus, similar to MDA-MB-231 breast cancer cells, high levels of insulin did not induce a uniform proliferative effect, even though insulin signalling seemed intact.
The most interesting question arising from the results presented in this study is what the physiological effect of insulin on ER-negative breast cancer cells is, given that insulin signalling is intact and for MDA-MB-231 breast cancer cells even amplified. While our results did not validate a previous explanation for insulin resistance in MDA-MB-231 breast cancer cells, it is still likely that ER-negative breast cancer cells may have acquired insulin resistance. If the condition of ER negativity in cells was regarded as an enhancer of breast cancer progression and not an ab initio determinant, it could be speculated that acquired insulin resistance may be an additional feature of breast cancer progression. This would explain the connection of induced cell proliferation in ER-positive but not in ER-negative cells.
MCF-10A breast epithelial cells were also analysed following insulin treatment. Similar to the breast cancer cell lines, normal insulin signalling, IR phosphorylation and AKT and ERK1/2 phosphorylation, were intact. The increase in the phosphorylation of these pathways was similar to that observed for the SK-BR-3 but not the MDA-MB-231 breast cancer cell line, further emphasizing the highly aberrant insulin signalling in MDA-MB-231 breast cancer cells. In contrast to the effects in both breast cancer cell lines, however, insulin treatment induced cell proliferation in MCF-10A cells and a significant decrease in apoptosis. These results suggest a significant physiological impact of insulin on cell growth and reduction of apoptosis in these non-malignant epithelial cells. Clearly, there is sufficient evidence to suggest a significant growth-promoting and survivalinducing effect of insulin on MCF-10A breast epithelial cells. This is a novel finding and may suggest that insulin could play a role in the aetiology of postmenopausal breast cancer attributable to obesity.
Epithelial cells rather than breast cancer cells may be more susceptible to insulin-induced proliferative pressure. Thus, insulin may have a greater impact on breast cancer aetiology than on breast cancer progression (at least for progression of ER-negative breast cancers). This may provide a novel molecular explanation for the frequently proposed, but unsatisfactorily explained role of insulin in the promotion of increased postmenopausal breast cancer risk in obese women. * p<0.05, denotes a significant difference compared to the control, obtained using Dunnett's post hoc t-test following univariate analysis of variance.
